Pegasus Biotech, a leading biotechnology contract research organization, has announced the development of a revolutionary plasmid technology that enables precise control over DNA replication. Dr. Patrick Slaine, Chief Science Officer at Pegasus, stated that their new BPE plasmid technology utilizes a patented origin that can lay dormant during fermentation and trigger replication at high cell densities, resulting in significantly higher replication levels compared to existing technology.
The BPE plasmid technology does not use an antibiotic resistance selection marker and contains minimal bacterial sequences, less than 1,000 base pairs. This makes it ideal for applications where cost of goods sold and patient safety are important factors. Additionally, the technology offers enhanced expression, with cells transfected with BPE plasmid showing up to 7 times more expression than conventional plasmid backbones.
Pegasus Biotech specializes in ensuring that client projects comply with global regulations and result in commercially viable products. Their services include seed-to-formulation process development and associated analytical development. For more information on Pegasus’ services, visit their website.
The project required low cost, minimal bacterial sequences, high expression, and no antibiotic resistance selection marker – all of which are characteristics of this new technology. Daniel Wilson, the COO of Pegasus Biotech emphasized the transformational nature of this technology especially in applications where cost of goods sold and patient safety are important factors.
Pegasus Biotech Inc., is a full-service biotechnology contract research organization that offers process and analytical development services to the global pharmaceutical industry. Specializing in vaccine and biopharmaceutical development, they are global leaders in DNA vaccine development
